Share on LinkedInShare on LinkedIn

ARTICLE · 14 OCTOBER 2019

Amgen And Sanofi: What Does It Take To Patent An Antibody?

The next steps and lessons learned from the latest chapter in the dispute between Amgen and Sanofi: What does it now take to patent an antibody?

IsraelIntellectual Property

The next steps and lessons learned from the latest chapter in the dispute between Amgen and Sanofi: What does it now take to patent an antibody?

Biologics are an increasing share of the pharmaceutical market, and many of them are monoclonal antibody drugs. For broad claims to such antibodies, satisfying the written description and enablement requirements is becoming more difficult, as can be seen in an ongoing patent dispute between Amgen and Sanofi for their monoclonal PCSK9 inhibitor antibody drugs for lowering cholesterol.

Amgen and its PCSK9 rivals Sanofi and Regeneron have been battling over their US patents for years. Here we discuss the most recent developments in that dispute.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from